AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Orexo Management Reports 2015

Sep 2, 2015

3093_rns_2015-09-02_8f9f449f-b3c1-4533-b5b9-5fc370a7aca4.pdf

Management Reports

Open in viewer

Opens in your device viewer

Press release

Letter to Orexo shareholders from CEO Nikolaj Sørensen

Uppsala, Sweden – September 2, 2015 – Orexo AB (publ) informs that the CEO of Orexo, Nikolaj Sørensen, today has sent a letter to all shareholders of the company. The letter provides an update on the commercialization of Zubsolv® and the sales progress in the U.S. market as well as a general business update. The letter is also available on the company's home page at www.orexo.com.

For further information, please contact

Nikolaj Sørensen, President and CEO Tel: +46 (0)18-780 88 00, E-mail: [email protected]

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden. www.orexo.com.

For information about ZUBSOLV and opioid dependence, please visit www.zubsolv.com and www.outthemonster.com